X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Study aims to evaluate effects of icosapent ethyl (VASCEPA®) (IPE) on laboratory-confirmed viral upper respiratory infection (URI) rates, clinical impact and outcomes, especially with SARS-CoV-2 infection in adults with established atherosclerotic cardiovascular disease.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Vascepa
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amarin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 07, 2020
Details:
Kaiser Permanente to join as a governing member with the goal of helping to secure supplies of essential generic medications during COVID-19 and beyond.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Civica Rx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
